biotech · Hypertriglyceridemia · Candidiasis, Chronic Mucocutaneous · MTNB
Matinas BioPharma Holdings
Matinas BioPharma Holdings clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Bedminster, USA
- Founded
- 2011
- Employees
- 16
- Programs
- 9
- Drugs
- 5
- Patents
- 8
Matinas BioPharma Holdings projects
7 ClinicalTrials.gov programs sponsored by Matinas BioPharma Holdings.
Matinas BioPharma Holdings has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Amphotericin B
Matinas BioPharma Holdings
Candidiasis, Chronic Mucocutaneous
1 trial -
Drug Omega 3
Matinas BioPharma Holdings
Hypertriglyceridemia
1 trial -
Encochleated Amphotericin B
Matinas BioPharma Holdings
Cryptococcal Infections
1 trial -
Omega 3 pentaenoic acid
Matinas BioPharma Holdings
Hypertriglyceridemia
1 trial -
Oral Encochleated Amphotericin B (CAMB)
Matinas BioPharma Holdings
Acute Myeloid Leukemia
1 trial -
Oral Encochleated Amphotericin B (CAMB)
Matinas BioPharma Holdings
Vulvovaginal Candidiases
1 trial -
Oral Encochleated Amphotericin B (CAMB)
Matinas BioPharma Holdings
Vulvovaginitis
1 trial
Frequently asked questions
How many clinical projects does Matinas BioPharma Holdings have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.